Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) is set to issue its quarterly earnings data before the market opens on Tuesday, October 29th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.
Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) last issued its quarterly earnings data on Tuesday, July 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.02. During the same quarter in the previous year, the business earned ($0.13) earnings per share. On average, analysts expect Nautilus Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Nautilus Biotechnology Trading Down 1.1 %
Shares of NAUT opened at $2.69 on Monday. The firm has a market cap of $336.96 million, a P/E ratio of -4.89 and a beta of 1.22. Nautilus Biotechnology has a 12-month low of $2.19 and a 12-month high of $3.45. The company’s 50-day moving average price is $2.73 and its 200 day moving average price is $2.61.
Insider Buying and Selling at Nautilus Biotechnology
Nautilus Biotechnology Company Profile
Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
See Also
- Five stocks we like better than Nautilus Biotechnology
- Conference Calls and Individual Investors
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- What Does Downgrade Mean in Investing?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.